The estimated Net Worth of Rock Ventures Iii, L.P.Thir... is at least $78.7 Million dollars as of 30 January 2023. Rock Thir owns over 388,642 units of Pliant Therapeutics stock worth over $57,441,668 and over the last 2 years Rock sold PLRX stock worth over $21,225,234.
Rock has made over 8 trades of the Pliant Therapeutics stock since 2022, according to the Form 4 filled with the SEC. Most recently Rock sold 388,642 units of PLRX stock worth $3,587,166 on 30 January 2023.
The largest trade Rock's ever made was selling 483,815 units of Pliant Therapeutics stock on 12 August 2022 worth over $2,951,272. On average, Rock trades about 177,149 units every 20 days since 2022. As of 30 January 2023 Rock still owns at least 4,685,291 units of Pliant Therapeutics stock.
You can see the complete history of Rock Thir stock trades at the bottom of the page.
Over the last 4 years, insiders at Pliant Therapeutics have traded over $16,925,448 worth of Pliant Therapeutics stock. The most active insiders traders include Group, Llc Green Jeremy Red..., Rock Ventures Iii, L.P.Thir... und Thomas A Mccourt. On average, Pliant Therapeutics executives and independent directors trade stock every 24 days with the average trade being worth of $221,612. The most recent stock trade was executed by Eric Lefebvre on 10 July 2024, trading 12,319 units of PLRX stock currently worth $142,408.
Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, which is in three Phase 2a trials. The company also develops PLN-1474, a small-molecule selective inhibitor of avß1, which completed Phase 1 clinical trial for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis. In addition, it is developing two additional preclinical integrin-based programs, which include an oncology program, as well as a program for an allosteric agonistic monoclonal antibody against an undisclosed integrin receptor for treatment of muscular dystrophies, including duchenne muscular dystrophy. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.
Pliant Therapeutics executives and other stock owners filed with the SEC include: